Gapping up
In reaction to strong earnings/guidance: NCFT +13.5%, ARCP +1%, NPD +0.5%
M&A news: ICEL +108.9% (to be acquired by Fujifilm for $ 16.50 per share), ASPX +41.5% (to be acquired by Teva Pharma (TEVA) for $101.00 per share), CTRX +25% (to be acquired by UnitedHealth Group's (UNH) OptumRx business for $61.50 per share in cash), NCFT +13.5% (agrees to be acquired by Fortune Brands (FBHS) for $25.50/share in cash), HPTX+7.3% (to be acquired by Horizon Pharma (HZNP) for $46.00 per share in cash or ~$1.1 bln on a fully diluted basis), MSG +5.9% (announces filing of Form 10 Registration Statement for separation of sports and entertainment business from media business; upgraded to Overweight from Equal-Weight at Morgan Stanley), UNH +4.1%
Select China related names trading higher: SHI +10.8%, SFUN +5.7%, EJ +5.4%, LEJU +4.9%, ZNH +3.2%, QIHU +1.7%, CTRP +1.7%, YY +1.4%, BIDU +0.8%
Other news: CNET +23.2% (has entered a service partner agreement with Baidu (BIDU) to cross-sell branded services and products), ZIOP +14.3% (ZIOPHARM and Intrexon Corporation (XON) announce a new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono (MKGAY.PK)), XON+13.8%, LAYN +8.2% ( announces award of new contracts valued at ~$110 million), LBIO +7.1% (announces positive data from a TIL-Ipilimumab combination study in melanoma), DWA +6.2% (Home pulled in $54 mln at the box office in its opening weekend, well above estimates), CLDN +5.7% (Enterprise Partners Management discloses 8.3% passive stake in 13G filing), SYN +5.6% (announces it has initiated a Phase 2a clinical trial of SYN-004), NVAX +4.6% (presents new data from non-human primate Ebola challenge), MAGS +3.5% (announces award of $12 million in new orders), DEI +2.2% (to join the S&P MidCap 400), ESPR +1.6% (Visium Asset Management discloses 6.4% passive stake in 13G filing), JPM+1.4% (still checking), MDLZ +1.3% (may sell rights to Philadelphia cream cheese, according to SundayTimes), AA +1% (to curtail smelting capacity in Brazil; curtailment is expected to be complete by April 15, 2015)
Analyst comments: SMMT +4.4% (initiated with a Outperform at Oppenheimer), ADI +3.3% (upgraded to Overweight from Equal Weight at Barclays ), GPRO +2.8% (upgraded to Buy from Neutral at Dougherty & Company), RH +2.1% (upgraded to Buy from Neutral at Goldman), HTZ +2.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley), ABGB+1.8% (upgraded to Neutral at Exane BNP Paribas), NKE +1.6% (upgraded to Outperform from Neutral at Robert W. Baird), CLR +1.5% (upgraded to Buy from Hold at Societe Generale), RIG +1.4% (upgraded to Neutral at Global Hunter), WU +1.2% (upgraded to Buy from Hold at Evercore ISI), ORCL +1.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts ), TIVO +1.1% (initiated with a Outperform at Macquarie), BRCM +1% (upgraded to Buy from Neutral at Nomura), FINL +1% (upgraded to Buy from Neutral at Monness Crespi & Hardt)
In reaction to strong earnings/guidance: NCFT +13.5%, ARCP +1%, NPD +0.5%
M&A news: ICEL +108.9% (to be acquired by Fujifilm for $ 16.50 per share), ASPX +41.5% (to be acquired by Teva Pharma (TEVA) for $101.00 per share), CTRX +25% (to be acquired by UnitedHealth Group's (UNH) OptumRx business for $61.50 per share in cash), NCFT +13.5% (agrees to be acquired by Fortune Brands (FBHS) for $25.50/share in cash), HPTX+7.3% (to be acquired by Horizon Pharma (HZNP) for $46.00 per share in cash or ~$1.1 bln on a fully diluted basis), MSG +5.9% (announces filing of Form 10 Registration Statement for separation of sports and entertainment business from media business; upgraded to Overweight from Equal-Weight at Morgan Stanley), UNH +4.1%
Select China related names trading higher: SHI +10.8%, SFUN +5.7%, EJ +5.4%, LEJU +4.9%, ZNH +3.2%, QIHU +1.7%, CTRP +1.7%, YY +1.4%, BIDU +0.8%
Other news: CNET +23.2% (has entered a service partner agreement with Baidu (BIDU) to cross-sell branded services and products), ZIOP +14.3% (ZIOPHARM and Intrexon Corporation (XON) announce a new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono (MKGAY.PK)), XON+13.8%, LAYN +8.2% ( announces award of new contracts valued at ~$110 million), LBIO +7.1% (announces positive data from a TIL-Ipilimumab combination study in melanoma), DWA +6.2% (Home pulled in $54 mln at the box office in its opening weekend, well above estimates), CLDN +5.7% (Enterprise Partners Management discloses 8.3% passive stake in 13G filing), SYN +5.6% (announces it has initiated a Phase 2a clinical trial of SYN-004), NVAX +4.6% (presents new data from non-human primate Ebola challenge), MAGS +3.5% (announces award of $12 million in new orders), DEI +2.2% (to join the S&P MidCap 400), ESPR +1.6% (Visium Asset Management discloses 6.4% passive stake in 13G filing), JPM+1.4% (still checking), MDLZ +1.3% (may sell rights to Philadelphia cream cheese, according to SundayTimes), AA +1% (to curtail smelting capacity in Brazil; curtailment is expected to be complete by April 15, 2015)
Analyst comments: SMMT +4.4% (initiated with a Outperform at Oppenheimer), ADI +3.3% (upgraded to Overweight from Equal Weight at Barclays ), GPRO +2.8% (upgraded to Buy from Neutral at Dougherty & Company), RH +2.1% (upgraded to Buy from Neutral at Goldman), HTZ +2.1% (upgraded to Equal-Weight from Underweight at Morgan Stanley), ABGB+1.8% (upgraded to Neutral at Exane BNP Paribas), NKE +1.6% (upgraded to Outperform from Neutral at Robert W. Baird), CLR +1.5% (upgraded to Buy from Hold at Societe Generale), RIG +1.4% (upgraded to Neutral at Global Hunter), WU +1.2% (upgraded to Buy from Hold at Evercore ISI), ORCL +1.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts ), TIVO +1.1% (initiated with a Outperform at Macquarie), BRCM +1% (upgraded to Buy from Neutral at Nomura), FINL +1% (upgraded to Buy from Neutral at Monness Crespi & Hardt)